Trial
NCT02306811
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Relapsing-remitting Multiple Sclerosis
Intervention
Vatelizumab
Why stopped
Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-21